TY - JOUR
T1 - Risk of hidradenitis suppurativa comorbidities over time
T2 - A prospective cohort study of danish blood donors
AU - Andersen, Rune Kjærsgaard
AU - Loft, Isabella Charlotte
AU - Burgdorf, Kristoffer
AU - Erikstrup, Christian
AU - Pedersen, Ole B.
AU - Jemec, Gregor B.E.
PY - 2021
Y1 - 2021
N2 - Hidradenitis suppurativa is a common recurrent inflammatory skin disease. It is associated with multiple comorbidities whose temporal relationships are unknown due to long diagnostic delays. This study of otherwise healthy blood donors with self-reported symptoms of hidradenitis suppurativa investigated the temporal relationships of comorbidities. A prospective survival analysis on a nationwide cohort of blood donors, using registry data on drug prescription, was used to calculate the hazard ratio of time until first prescription of medical treatment for the following hidradenitis suppurativa-related comorbidities: heart disease, diabetes, depression, thyroid disease and pain. Hidradenitis suppurativa status was determined by a validated questionnaire, and the survival analysis was adjusted for age, sex, body mass index, smoking status and having an International Classification of Diseases Version 10 (ICD-10) diagnosis of hidradenitis suppurativa. Of the participants, 1,012 reported hidra-denitis suppurativa symptoms, and these symptoms increased the hazard ratio of antidepressants (1.73, 95% confidence interval 1.17–2.56, p ≈ 0.006) and analgesics (hazard ratio 1.24, 95% confidence interval 1.11–1.39, p < 0.001). Pain and depression are the first comorbidities to present in hidradenitis suppura-tiva pathogenesis.
AB - Hidradenitis suppurativa is a common recurrent inflammatory skin disease. It is associated with multiple comorbidities whose temporal relationships are unknown due to long diagnostic delays. This study of otherwise healthy blood donors with self-reported symptoms of hidradenitis suppurativa investigated the temporal relationships of comorbidities. A prospective survival analysis on a nationwide cohort of blood donors, using registry data on drug prescription, was used to calculate the hazard ratio of time until first prescription of medical treatment for the following hidradenitis suppurativa-related comorbidities: heart disease, diabetes, depression, thyroid disease and pain. Hidradenitis suppurativa status was determined by a validated questionnaire, and the survival analysis was adjusted for age, sex, body mass index, smoking status and having an International Classification of Diseases Version 10 (ICD-10) diagnosis of hidradenitis suppurativa. Of the participants, 1,012 reported hidra-denitis suppurativa symptoms, and these symptoms increased the hazard ratio of antidepressants (1.73, 95% confidence interval 1.17–2.56, p ≈ 0.006) and analgesics (hazard ratio 1.24, 95% confidence interval 1.11–1.39, p < 0.001). Pain and depression are the first comorbidities to present in hidradenitis suppura-tiva pathogenesis.
KW - Analgesia
KW - Antidepressants
KW - Comorbidity
KW - Hidradenitis suppurativa
KW - Pre-scription
KW - Survival analysis
U2 - 10.2340/00015555-3737
DO - 10.2340/00015555-3737
M3 - Journal article
C2 - 33372684
AN - SCOPUS:85100280171
VL - 101
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
M1 - adv00376
ER -